search
Back to results

Implementation of Evidence-Based Practice for Dizziness (DIZZTINCT2)

Primary Purpose

BPPV, Vestibular Diseases, Vertigo

Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
CME Educational Intervention
Study Developed Educational Materials for Patients
Sponsored by
Ohio State University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional health services research trial for BPPV

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Age >= 18 years Dizziness diagnosis as the primary discharge diagnosis (ICD-10 codes: R42.xx "Dizziness"; H81.xx "Disorders of vestibular system" (e.g., BPPV, vestibular neuritis); H82.xx "Other vertiginous syndromes"; H83.xx "Other diseases of inner ear"; R26.0 "Ataxic gait"; R26.2 "Difficulty in walking"; R26.81 "Unsteadiness on feet"; R26.89 "Other abnormalities of gait"; R27.xx "Other lack of coordination"; A88.1 "Epidemic vertigo") Discharged home from ED or Observation from one of 14 Kaiser Permanente Southern California (KPSC) Emergency Departments within the last 48 hours (Enrolled population) Continuous health plan membership in the last 31 days prior to the encounter English or Spanish speaker Exclusion Criteria: Prisoners Death Level 1 trauma diagnosis Previously enrolled in study Does not demonstrate capacity to consent assessed by the Older Adults' Capacity to Consent to Research (OACCR) scale48

Sites / Locations

  • Kaiser Permanente Southern CaliforniaRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm 6

Arm Type

Experimental

No Intervention

No Intervention

Experimental

Experimental

Experimental

Arm Label

Group 1: Pre-CME with Patient Education

Group 2: Pre-CME with Standard Patient Care

Group 3: Pre-CME with Chart Review Only

Group 4: Post-CME with Patient Education

Group 5: Post-CME with Standard Patient Care

Group 6: Post-CME with Chart Review Only

Arm Description

Physicians in hospitals that have not received the DIZZTINCT educational intervention. Patients have received the DIZZTINCT educational intervention

Physicians in hospitals that have not received the DIZZTINCT educational intervention. Patients have not received the DIZZTINCT educational intervention

Physicians in hospitals that have not received the DIZZTINCT educational intervention. Eligible patient will have their medical records abstracted to assess the main study outcome

Physicians in hospitals that have received the DIZZTINCT educational intervention. Patients have receive the DIZZTINCT educational intervention

Physicians in hospitals that have received the DIZZTINCT educational intervention. Patients have not receive the DIZZTINCT educational intervention

Physicians in hospitals that have received the DIZZTINCT educational intervention. Eligible patient will have their medical records abstracted to assess the main study outcome

Outcomes

Primary Outcome Measures

Documentation of Dix-Hallpike Test/Canalith Repositioning Maneuver
To determine whether patient received a BPPV Care Process. Pre-CME vs Post CME. The primary endpoint is measured at the individual patient level and is the presence of documentation of either the Dix-Hallpike Test or the Canalith Repositioning Maneuver
Dizziness Handicap Inventory
To assess patient dizziness disability over time. The primary endpoint is a patient reported outcome collected weekly for 4 weeks using computerized surveys.

Secondary Outcome Measures

Full Information

First Posted
November 23, 2022
Last Updated
December 1, 2022
Sponsor
Ohio State University
Collaborators
National Institute on Deafness and Other Communication Disorders (NIDCD), Kaiser Permanente, University of Michigan
search

1. Study Identification

Unique Protocol Identification Number
NCT05634902
Brief Title
Implementation of Evidence-Based Practice for Dizziness
Acronym
DIZZTINCT2
Official Title
Dizziness Treatment Through Implementation & Clinical Strategy Tactics
Study Type
Interventional

2. Study Status

Record Verification Date
November 2022
Overall Recruitment Status
Recruiting
Study Start Date
November 11, 2022 (Actual)
Primary Completion Date
December 2024 (Anticipated)
Study Completion Date
December 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Ohio State University
Collaborators
National Institute on Deafness and Other Communication Disorders (NIDCD), Kaiser Permanente, University of Michigan

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The study evaluates the implementation of evidence-based practice for the management of patients with dizziness in the emergency department (ED) within a large integrated health care system. The clinical focus is on benign paroxysmal positional vertigo (BPPV), unilateral vestibulopathy (e.g., vestibular neuritis), and stroke - which are disorders with established evidence-base practices for evaluation and management. Evidence-based practices for these clinical topics have not properly disseminated regarding dizziness visits, and this results in missed opportunities for effective and efficient care delivery. The investigators propose a hybrid type 3 effectiveness-implementation trial to evaluate an enhanced BPPV-centric implementation strategy and clinical intervention. The overall strategy, initially developed in Dizziness Treatment through Implementation & Clinical strategy Tactics-1 (DIZZTINCT-1), will be improved to increase generalizability, convenience, exposures, sustainability, and dissemination. We use an innovative design of a stepped-wedge trial for the ED-level implementation strategy and an embedded randomized patient-level dissemination strategy. As a result, we can closely assess the individual and additive impact of study components. We will evaluate effectiveness of the implementation strategy and also confirm clinical outcomes.
Detailed Description
Current management of dizziness in the ED often leads to expensive, time consuming, and unnecessary tests, but not appropriate evidence-based and guideline concordant evaluation & management. The Dix-Hallpike Test (DHT) and Canalith Repositioning Maneuver (CRM) are used to diagnose and treat Benign Paroxysmal Positional Vertigo (BPPV). BPPV processes have an evidence base that is at the clinical practice guideline level. The DHT is the gold standard test for DHT and the CRM is supported by numerous randomized controlled trials and systematic reviews. Gaze stabilization exercises are also evidence-based treatment for unilateral vestibulopathy. The problem is that evidence based processes of care for dizziness visits are frequently underutilized. An ED- level stepped wedge randomized clinical trial with an embedded patient- level randomized controlled dissemination strategy will be used to increase the use of evidence based care using a theory-based education intervention within a large integrated health care system. The trial will begin with an initial no intervention period followed by a randomized staggered intervention at the 14 EDs in 11 waves (some medical centers will be paired based on the medical service area). The physician-based intervention consists of a recorded continuing medical education (CME) session, a mobile responsive website with the recommended algorithm of care, print materials (posters and note cards) and a dot phrase for dizziness. We will evaluate documentation of the DHT and CRM in approximately 80,000 dizziness visits. Concurrently, eligible patients with a dizziness-related emergency department visit will be identified from the electronic medical records (EMR) system before and after the physician level intervention is implemented at each ED. Enrolled subjects will be randomized individually to the intervention or control arm using central computerized randomization. The patient-based intervention includes patient-oriented materials focused on evidence based care incorporated into a patient-specific website. We plan to have 800 patients for the analysis. The primary outcome for the ED-level implementation strategy is DHT or CRM documentation. The primary outcome measure for the patient-level intervention is the Dizziness Handicap Inventory (DHI). The overall potential public health impact of improved ED dizziness care is substantial based on the volume of visits, underuse of effective management, and inefficiencies from overuse of typically unnecessary tests.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
BPPV, Vestibular Diseases, Vertigo, Dizziness

7. Study Design

Primary Purpose
Health Services Research
Study Phase
Not Applicable
Interventional Study Model
Factorial Assignment
Masking
Participant
Allocation
Randomized
Enrollment
80000 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Group 1: Pre-CME with Patient Education
Arm Type
Experimental
Arm Description
Physicians in hospitals that have not received the DIZZTINCT educational intervention. Patients have received the DIZZTINCT educational intervention
Arm Title
Group 2: Pre-CME with Standard Patient Care
Arm Type
No Intervention
Arm Description
Physicians in hospitals that have not received the DIZZTINCT educational intervention. Patients have not received the DIZZTINCT educational intervention
Arm Title
Group 3: Pre-CME with Chart Review Only
Arm Type
No Intervention
Arm Description
Physicians in hospitals that have not received the DIZZTINCT educational intervention. Eligible patient will have their medical records abstracted to assess the main study outcome
Arm Title
Group 4: Post-CME with Patient Education
Arm Type
Experimental
Arm Description
Physicians in hospitals that have received the DIZZTINCT educational intervention. Patients have receive the DIZZTINCT educational intervention
Arm Title
Group 5: Post-CME with Standard Patient Care
Arm Type
Experimental
Arm Description
Physicians in hospitals that have received the DIZZTINCT educational intervention. Patients have not receive the DIZZTINCT educational intervention
Arm Title
Group 6: Post-CME with Chart Review Only
Arm Type
Experimental
Arm Description
Physicians in hospitals that have received the DIZZTINCT educational intervention. Eligible patient will have their medical records abstracted to assess the main study outcome
Intervention Type
Behavioral
Intervention Name(s)
CME Educational Intervention
Intervention Description
The educational materials for physicians include a recorded CME session, a mobile responsive website with the recommended algorithm of care, print materials (posters and note cards) and a dot phrase for dizziness.
Intervention Type
Behavioral
Intervention Name(s)
Study Developed Educational Materials for Patients
Intervention Description
Patient-oriented materials are incorporated into a mobile responsive website with information/instruction about BPPV, and self-management resources; information/instruction on gaze stabilization exercises for vestibular neuritis
Primary Outcome Measure Information:
Title
Documentation of Dix-Hallpike Test/Canalith Repositioning Maneuver
Description
To determine whether patient received a BPPV Care Process. Pre-CME vs Post CME. The primary endpoint is measured at the individual patient level and is the presence of documentation of either the Dix-Hallpike Test or the Canalith Repositioning Maneuver
Time Frame
Index ED 1 day visit
Title
Dizziness Handicap Inventory
Description
To assess patient dizziness disability over time. The primary endpoint is a patient reported outcome collected weekly for 4 weeks using computerized surveys.
Time Frame
Cumulative 4 weeks following index ED visit

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age >= 18 years Dizziness diagnosis as the primary discharge diagnosis (ICD-10 codes: R42.xx "Dizziness"; H81.xx "Disorders of vestibular system" (e.g., BPPV, vestibular neuritis); H82.xx "Other vertiginous syndromes"; H83.xx "Other diseases of inner ear"; R26.0 "Ataxic gait"; R26.2 "Difficulty in walking"; R26.81 "Unsteadiness on feet"; R26.89 "Other abnormalities of gait"; R27.xx "Other lack of coordination"; A88.1 "Epidemic vertigo") Discharged home from ED or Observation from one of 14 Kaiser Permanente Southern California (KPSC) Emergency Departments within the last 48 hours (Enrolled population) Continuous health plan membership in the last 31 days prior to the encounter English or Spanish speaker Exclusion Criteria: Prisoners Death Level 1 trauma diagnosis Previously enrolled in study Does not demonstrate capacity to consent assessed by the Older Adults' Capacity to Consent to Research (OACCR) scale48
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Kevin Kerber, MD
Phone
734-478-2678
Email
Kevin.Kerber@osumc.edu
First Name & Middle Initial & Last Name or Official Title & Degree
Huong Nguyen, PhD
Phone
626-773-0873
Email
huong.q2.nguyen@kp.org
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Kevin Kerber, MD
Organizational Affiliation
Ohio State University
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Will Meurer, MD
Organizational Affiliation
University of Michigan
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Huong Nguyen, PhD
Organizational Affiliation
Kaiser Permanente
Official's Role
Principal Investigator
Facility Information:
Facility Name
Kaiser Permanente Southern California
City
Pasadena
State/Province
California
ZIP/Postal Code
91101
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Huong Nguyen, PhD
Phone
626-773-0873
Email
huong.q2.nguyen@kp.org

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
The investigators are committed to resource and data sharing with the clinical research community. Optimally effective data sharing is carefully planned. The specific contents and strategy for creating and sharing a public use dataset will be established at the beginning of the trial, rather than at the end. The primary results of the study will be disseminated by publication in the peer reviewed medical literature. In accordance with the NIH Public Access Policy, the investigators will submit an electronic version of their final, peer-reviewed manuscripts (directly or through the publisher) to the National Library of Medicine's PubMed Central, no later than 12 months after the official date of publication. The trial will be registered with http://www.ClinicalTrials.gov, and results of the study will be reported there within a year of study completion.
IPD Sharing Time Frame
We plan to submit data to the repository approximately one year after the primary manuscript of the trial is accepted for publication
IPD Sharing Access Criteria
We plan to make the data publicly available in accordance with approval and regulations of Kaiser Permanente and the funding Institute. The location of study data repository will be arranged with the Institute and Kaiser Permanente. The public use dataset will be stripped of any and all personal identifiers and will undergo a deidentification process. Our HIPAA compliant de-identification plan is to remove study identification (ID) numbers and assignment of a random number to each subject/visit, delete facility numbers and assignment of a random number to each facility, delete any investigator or assessor name/ID, delete the randomization date but retain the month and year and the order of visits and enrollment, and convert when necessary dates and times to the number of days/minutes from the date and time of randomization. Derived variables necessary to reproduce the primary analysis will be included.

Learn more about this trial

Implementation of Evidence-Based Practice for Dizziness

We'll reach out to this number within 24 hrs